Company news

IDEAYA Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day

February 21, 2021

IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors

February 16, 2021

IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs

February 7, 2021

IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

January 10, 2021

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

January 4, 2021

IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index

December 13, 2020

IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

November 11, 2020

IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform

October 21, 2020

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

September 23, 2020

IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

August 11, 2020

IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment

August 3, 2020

IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial

July 15, 2020

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor

July 8, 2020

IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics

June 29, 2020

IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology

June 15, 2020

IDEAYA Biosciences Selected to Join Russell 3000® Index

June 10, 2020

IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population

June 7, 2020

IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program

May 14, 2020

IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team

April 20, 2020

IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update

March 23, 2020

IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update

March 17, 2020

IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities

March 10, 2020

IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020

January 14, 2020

IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

November 12, 2019

IDEAYA Biosciences Announces Leadership Updates in Research Organization

November 4, 2019

IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

October 30, 2019

IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

August 11, 2019

IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations

July 8, 2019

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 27, 2019

IDEAYA Announces Pricing of Initial Public Offering

May 21, 2019

← Newer news releases

Decks

The 5 newest of 23 decks. Every deck is listed under its year.